Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in @entity1 with classic @entity978 (cHL) are poorly understood. We performed a comprehensive analysis of @entity1733 ( @entity1733 ). Methods To estimate the incidence of @entity1733 , we retrospectively analyzed 6,840 @entity1 with cHL included in the German Hodgkin Study Group trials @entity42237 to HD12. @entity1 who experienced a relapse > 5 years into remission were compared with @entity1 in continued remission for > 5 years and with those who experienced a relapse <=  5 years after first diagnosis. Results With a median observation time of 10.3 years, 141 incidences of @entity1733 were observed. Cumulative incidences at 10, 15, and 20 years rose linearly and were 2.5%, 4.3%, and 6.9%, respectively. The standardized incidence ratio for @entity1733 with respect to age- and sex-matched German reference data was 84.5 (95% CI, 71.2 to 99.7). @entity1733 was more frequently observed in @entity1 with early-stage favorable than unfavorable or advanced stage at first diagnosis (15-year cumulative incidence, 5.3% v 3.9% and 3.9%, respectively; P = .01). Overall survival from first diagnosis was worse after LR compared with nonrelapse survivors (10-year estimate, 95.8% v 86.1%; hazard ratio, 2.5; 95% CI, 1.7 to 3.5; P < .001). In @entity1 with @entity1733 , survival was better compared with 466 @entity1 with earlier relapse (hazard ratio, 0.6; 95% CI, 0.4 to 0.9, P = .01). Forty-four percent and 49% of @entity1 with @entity1733 and earlier relapse, respectively, received stem cell transplantations. Conclusion Apart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable @entity1733 , regular clinical follow-up is recommended for timely detection of @entity1733 . With adequate treatment, prognosis of @entity1733 is better compared with early relapses.

Late Relapse of @entity978 : An Analysis of the German Hodgkin Study Group XXXX to HD12 Trials.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity978 :: ('MESH:D006689', 'Disease') :: ['Hodgkin lymphoma'] @entity1733 :: ('MESH:C538324', 'Disease') :: ['LR-HL', 'HL', 'LR of Hodgkin lymphoma'] @entity42237 :: ('51564', 'Gene') :: ['HD7']
@entity42237 :: (51564,Gene) :: ['HD7']
